Vanguard Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-2,125,480
| Closed | -$7.87M | – | 4121 |
|
|
2017
Q4 | $7.87M | Buy |
2,125,480
+245,440
| +13% | +$1M | ﹤0.01% | 2940 |
|
|
2017
Q3 | $7.69M | Buy |
1,880,040
+112,359
| +6% | +$430K | ﹤0.01% | 2943 |
|
|
2017
Q2 | $6.57M | Buy |
1,767,681
+343,838
| +24% | +$1.36M | ﹤0.01% | 2982 |
|
|
2017
Q1 | $5.89M | Buy |
1,423,843
+766,725
| +117% | +$3.22M | ﹤0.01% | 2996 |
|
|
2016
Q4 | $2.83M | Buy |
657,118
+76,948
| +13% | +$497K | ﹤0.01% | 3242 |
|
|
2016
Q3 | $5.71M | Buy |
580,170
+24,945
| +4% | +$177K | ﹤0.01% | 2941 |
|
|
2016
Q2 | $3.14M | Sell |
555,225
-40,331
| -7% | -$274K | ﹤0.01% | 3197 |
|
|
2016
Q1 | $4.54M | Buy |
595,556
+48,226
| +9% | +$371K | ﹤0.01% | 3004 |
|
|
2015
Q4 | $7.29M | Buy |
547,330
+3,867
| +0.7% | +$66.6K | ﹤0.01% | 2808 |
|
|
2015
Q3 | $8.93M | Buy |
543,463
+14,479
| +3% | +$297K | ﹤0.01% | 2669 |
|
|
2015
Q2 | $11.9M | Buy |
528,984
+28,757
| +6% | +$455K | ﹤0.01% | 2582 |
|
|
2015
Q1 | $4.89M | Buy |
500,227
+121,280
| +32% | +$1.19M | ﹤0.01% | 3010 |
|
|
2014
Q4 | $4.32M | Buy |
378,947
+29,999
| +9% | +$326K | ﹤0.01% | 2972 |
|
|
2014
Q3 | $4.02M | Buy |
348,948
+29,762
| +9% | +$455K | ﹤0.01% | 2951 |
|
|
2014
Q2 | $6.21M | Buy |
319,186
+25,085
| +9% | +$443K | ﹤0.01% | 2733 |
|
|
2014
Q1 | $5.28M | Buy |
294,101
+60,344
| +26% | +$991K | ﹤0.01% | 2797 |
|
|
2013
Q4 | $2.47M | Sell |
233,757
-26,338
| -10% | -$294K | ﹤0.01% | 3109 |
|
|
2013
Q3 | $3.21M | Buy |
260,095
+2,386
| +0.9% | +$25.1K | ﹤0.01% | 2944 |
|
|
2013
Q2 | $2.41M | Buy |
+257,709
| New | +$3.31M | ﹤0.01% | 3001 |
|
Vanguard Group's CASC Position: Q1 2018 in Review
Vanguard Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 2,125,480 shares — an estimated $7.87M sold.
Vanguard Group first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $11.9M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Vanguard Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Vanguard Group sold 2,125,480 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $7.87M.
- Vanguard Group first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Vanguard Group's Cascadian Therapeutics, Inc. position peaked at $11.9M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Vanguard Group's 13F filing for Q1 2018, filed 15 May 2018.